GlassScriptPhysician profile
Aleksander Lekan
NPI 1225055262
$4,665.58
in general payments reported to CMS, 2019-2025
37 companies · $514 in 2025
The $514 reported for 2025 was more than what 90% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $758 · 2020: $558 · 2021: $581 · 2022: $965 · 2023: $733 · 2024: $556 · 2025: $514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,803.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $790.28 | 2019-2025 | Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $548.29 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $449.12 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $415.95 | 2020-2025 | |
| Glaxosmithkline, LLC. | $405.50 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Amarin Pharma, INC. | $234.91 | 2019-2022 | |
| Lilly USA, LLC | $189.86 | 2019-2023 | Mounjaro |
| Janssen Pharmaceuticals, INC | $189.23 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $182.14 | 2019-2023 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $177.00 | 2022-2024 | Uptravi |
| Insulet Corporation | $139.84 | 2025 | Omnipod |
| Abbott Laboratories | $138.65 | 2024 | Mitraclip |
| Amgen INC. | $124.99 | 2023 | Repatha |
| Jazz Pharmaceuticals INC. | $88.80 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $72.86 | 2019-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $66.53 | 2019-2020 | |
| Janssen Biotech, INC. | $56.57 | 2019-2022 | |
| Argenx US, INC. | $52.01 | 2022-2023 | Vyvgart |
| Celgene Corporation | $35.72 | 2019 | |
| Alexion Pharmaceuticals, INC. | $31.84 | 2023-2024 | Ultomiris |
| Neurelis, INC. | $28.67 | 2021-2025 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $27.39 | 2019 | |
| Boston Scientific Corporation | $22.26 | 2024 | Watchman Flx |
| Mylan Specialty L.P. | $19.46 | 2022 | |
| Neurocrine Biosciences, INC. | $17.68 | 2023 | Ingrezza, Ongentys |
| Philips North America LLC | $17.56 | 2020 | |
| Dexcom, INC. | $15.00 | 2022 | |
| Abbvie INC. | $15.00 | 2020 | |
| Hikma Pharmaceuticals USA | $14.81 | 2020 | |
| Harmony Biosciences LLC | $13.38 | 2020 | |
| Cvrx, INC. | $13.37 | 2024 | Barostim Neo System |
| Grifols USA, LLC | $12.57 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.16 | 2019 | |
| Incyte Corporation | $11.76 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.69 | 2022 | |
| Janssen Scientific Affairs, LLC | $11.40 | 2019 | |
| Eisai INC. | $11.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aleksander Lekan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.